Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.
Article Details
- CitationCopy to clipboard
Hu S, Mathijssen RH, de Bruijn P, Baker SD, Sparreboom A
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.
Br J Cancer. 2014 Feb 18;110(4):894-8. doi: 10.1038/bjc.2013.811. Epub 2014 Jan 7.
- PubMed ID
- 24398510 [ View in PubMed]
- Abstract
BACKGROUND: Several tyrosine kinase inhibitors (TKIs) can decrease docetaxel clearance in patients by an unknown mechanism. We hypothesised that these interactions are mediated by the hepatic uptake transporter OATP1B1. METHODS: The influence of 16 approved TKIs on transport was studied in vitro using HEK293 cells expressing OATP1B1 or its mouse equivalent Oatp1b2. Pharmacokinetic studies were performed with Oatp1b2-knockout and OATP1B1-transgenic mice. RESULTS: All docetaxel-interacting TKIs, including sorafenib, were identified as potent inhibitors of OATP1B1 in vitro. Although Oatp1b2 deficiency in vivo was associated with increased docetaxel exposure, single- or multiple-dose sorafenib did not influence docetaxel pharmacokinetics. CONCLUSION: These findings highlight the importance of identifying proper preclinical models for verifying and predicting TKI-chemotherapy interactions involving transporters.
DrugBank Data that Cites this Article
- Drug Transporters
Drug Transporter Kind Organism Pharmacological Action Actions Axitinib Solute carrier organic anion transporter family member 1B1 Protein Humans NoSubstrateInhibitorDetails Nilotinib Solute carrier organic anion transporter family member 1B1 Protein Humans UnknownInhibitorDetails Pazopanib Solute carrier organic anion transporter family member 1B1 Protein Humans UnknownInhibitorDetails Sorafenib Solute carrier organic anion transporter family member 1B1 Protein Humans UnknownInhibitorDetails